新型药用辅料在含油中药半浸膏片中的应用

目的：对中药含油半浸膏片的赋形剂进行筛选。方法：以片剂外观、硬度和崩解时间为评价指标，以复方消炎片为模型药物，比较筛选稀释剂、吸收剂、黏合剂和崩解剂处方。结果：选用糖粉作为稀释剂与黏合剂，微粉硅胶作为吸收剂和润滑剂。结论：本实验为中药含油半浸膏片研制与开发提供了实验数据。     

氯沙坦钾片剂的处方设计及其制备

目的:制备氯沙坦钾片.方法:分别考察稀释剂、崩解剂、黏合剂及包衣对氯沙坦钾片溶出度的影响.结果:采用乳糖、微晶纤维素为稀释剂,10%PVP为黏合剂,低取代羟丙基纤维素(L-HPC)为崩解剂,欧巴代包衣,制备的片剂溶出曲线与国外片基本相同.片剂外观优良,硬度适中,溶出性能良好.结论:该制备工艺操作简单、工艺成熟.     

含油中药浸膏片赋形剂的筛选

目的筛选含油中药浸膏片赋形剂。方法以外观、硬度、崩解度、脆碎度等为指标评价赋形剂对片剂成型性的影响。结果稀释剂选用糖粉，吸收剂选用辅料X，粘合剂选用微晶纤维素，崩解剂选用低取代羟丙基纤维素片剂成型性好。结论以上赋形剂适合于该片剂。     

琥乙红霉素片的溶出度改进

目的 改善琥乙红霉素片的溶出性能，提高溶出速率。方法 分别考察稀释剂、崩解剂、黏合剂对琥乙红霉素片溶出速率的影响。结果采用预胶化淀粉和微晶纤维素为稀释剂、12％PVPK30的70％乙醇溶液为黏合剂、L-HPC和膨速王合用为崩解剂，制备的片剂溶出曲线与利君沙片基本相同。结论 制备的琥乙红霉素片外观光洁，有较好的硬度及溶出速率，加速试验3个月质量稳定，达到原先的设计要求。     

流化床制粒法制备甲磺酸吉米沙星片

目的：探索流化床制粒法制备甲磺酸吉米沙星片的工艺参数。方法：以崩解时限为指标,对甲磺酸吉米沙星片的处方进行筛选。结果：500g甲磺酸吉米沙星,60gMCC作为填充剂,600m15％HPMC溶液作为黏合剂,20gCMS—Na作为崩解剂．可制得的颗粒能够制备崩解性能良好的片剂。结论：流化床制粒法解决了传统湿法制粒制备甲磺酸吉米沙星片所遇到的困难。     

拉西地平片的处方工艺研究

目的研究拉西地平片的处方工艺。方法以乳糖作为填充剂,淀粉作为崩解剂,聚维酮K30作为黏合剂,硬脂酸镁作为润滑剂设计试验方案。以制粒的难易程度、颗粒的流动性、片剂外观、崩解时限、硬度、脆碎度及体外溶出度为指标进行试验,筛选最佳处方组成及工艺。结果处方1和处方2溶出慢,溶出度低,溶出不完全。处方3溶出均一性良好,30min溶出结果与对照片接近。故采用处方3为最终处方及工艺。结论采用本处方及工艺制得的拉西地平片外观性状、重量差异、含量、溶出度均符合拉西地平片质量标准要求,且制备工艺简单,适合于工业化生产。     

复方盐酸小檗碱分散片的制备及其溶出度考察

目的 制备复方盐酸小檗碱分散片,并与市售片剂的溶出度进行比较。方法以微晶纤维素为填充剂,交联聚乙烯吡咯烷酮为崩解剂,湿法制粒制备分散片。制定质量标准和溶出度测定方法,并进行质量评价和溶出度比较。结果符合中国药典中有关分散片的要求,其体外溶出释药明显优于普通片。结论所制分散片处方合理,崩解快、溶出快而完全。     

硫酸氢氯吡格雷片的制备及其处方工艺优化

目的:制备硫酸氢氯吡格雷片并优化其处方工艺。方法:采用单因素试验联合相容性试验对片剂的填充剂、崩解剂、黏合剂、润滑剂和制备方法进行筛选;以黏冲情况和崩解时间的综合评分为指标,采用正交试验优选崩解剂[低取代羟丙基纤维素(L-HPC)]、润滑剂(氢化植物油和聚乙二醇6000)的用量,并进行验证;考察所制片剂与进口制剂(波立维)在水、p H 2.0盐酸盐缓冲液、p H 4.5磷酸盐缓冲液(PBS)、p H 6.8 PBS中的溶出情况并进行影响因素试验。结果:采用干法制粒,最优处方(1 000片)为硫酸氢氯吡格雷97.8 g、甘露醇84 g、预胶化淀粉36 g、L-HPC 8 g、氢化植物油8 g、聚乙二醇6000 6 g;所制片剂压片无黏冲现象且崩解时间适中,其与波立维在4种溶出介质中溶出曲线均相似;影响因素试验结果与波立维比较无明显差异。结论:成功制得硫酸氢氯吡格雷片,且处方合理、工艺可行、质量稳定可控。     

中药复方制剂胃平分散片的制备工艺研究

目的 研究胃平分散片的优选处方和制备工艺.方法 以制粒情况、片子的外观、崩解时间、脆碎度为考察指标,采用正交试验对分散片处方进行筛选.结果 以微晶纤维素为填充剂,硬脂酸镁为润滑剂,3%的乳糖,1%交联聚乙烯吡咯烷酮、4%低取代羧丙基纤维素和8%的羧甲基淀粉钠为黏合剂、崩解剂.按优化处方制备的胃平分散片在3 min内完全崩解,15 min溶出度达到90%以上.结论 本法研制的胃平分散片处方合理,工艺可行.     

非那雄胺包衣分散片的制备及体外溶出度测定

目的优化非那雄胺分散片的处方及制备工艺,测定其溶出度。方法采用湿法制粒压片,正交试验优化处方工艺。结果非那雄胺片的处方组成：稀释剂为40%微晶纤维素和50%乳糖,崩解剂为5%低取代羟丙基纤维素,黏合剂为5%聚维酮K3025%的乙醇溶液,包衣液为15%的85G型欧巴代,45 min时溶出度可达90%以上。结论自制非那雄胺片质量稳定,工艺可靠,适合工业化生产要求。     

枸橼酸莫沙必利口腔崩解片的制备及评价

目的制备枸橼酸莫沙必利口腔崩解片并对其进行评价。方法在预实验的基础上选择处方中所用辅料,以口腔中崩解时间为考察指标,综合运用效应面图和等高线图对口腔崩解片处方进行优化,直接压片法压片,并对枸橼酸莫沙必利口腔崩解片溶出度进行了考察。结果枸橼酸莫沙必利口腔崩解片的最佳处方为枸橼酸莫沙必利5 mg、微晶纤维素76 mg、甘露醇97 mg、低取代羟丙基纤维素20 mg、橘子香精1 mg、硬脂酸富马酸钠1 mg。口腔中崩解时间为19.4 s,溶出度为99.7%。结论采用直接压片法制备枸橼酸莫沙必利口腔崩解片,崩解时间短、溶出速度快、口感好。     

血塞通脉冲控释片的处方优化

目的:优化血塞通脉冲控释片的处方。方法:采用单因素试验考察片芯崩解剂种类、片芯崩解剂用量、包衣液组成和包衣增重百分率对药物累积释放率的影响;采用正交试验考察片芯崩解剂用量、包衣液组成、包衣增重百分率对释药时滞时间的影响,优化血塞通脉冲控释片的处方。结果:最佳处方为片芯崩解剂用量为15%,包衣增重百分率为9%,包衣液组成为Eudragit L100∶EC=1.5∶1(m/m);在该处方条件下,血塞通脉冲片的体外释药时滞为6 h左右,然后迅速脉冲式释药。结论:所选处方合理,制备的血塞通脉冲控释片能达到设计要求,体外试验可达到脉冲释药时滞效果。     

Studies on cyclodextrin polymer. Part 1: The effect of CDP on indomethacin tablet formulation

Cyclodextrin polymer (CDP), which is a cross-linked derivative of beta-cyclodextrin, has been used as binder and disintegrating agent in tablet formulation. In this study different tablet formulations of indomethacin, which is a nonsteroid anti-inflammatory drug were prepared by direct compression method. Corn starch, lactose and Esma-Spreng were used besides CDP as disintegrating agent. The hardness, friability, disintegration time and dissolution rate of the tablet were determined. The data were also evaluated kinetically. It was found that CDP is a good disintegrating agent and significantly increased the dissolution rate of the poorly soluble indomethacin.     

对乙酰氨基酚口腔崩解片的研制

目的 以对乙酰氨基酚（扑热息痛）为模型药物制备新型口服速释剂型口腔崩解片。方法 以崩解时间为指标，采用正交试验筛选片剂的处方组成，并优化制备工艺。结果 以MCC／L-HPC 50：15作为崩解剂，部分制粒压片工艺制得的扑热息痛口腔崩解片，体外平均崩解时间为35s，置于口腔40s内可崩解，无砂砾感，片剂体外溶出度1min可达95％。结论 扑热息痛口腔崩解片于口腔内可迅速崩解，制备工艺简单可行，有效地改善了药物粉末的流动性，适宜于大生产。     

硫酸吗啡口腔崩解片的制备及处方工艺研究

目的:制备硫酸吗啡口腔崩解片,优化其处方工艺条件。方法:采用直接压片法制备硫酸吗啡口腔崩解片,以崩解时间和口感为指标采用单因素试验法筛选片剂硬度、硬脂酸镁用量、甜菊苷用量范围等,再以崩解时限为指标采用星点设计法优化微晶纤维素(SMCC)、交联羧甲基纤维素钠(CCMC-Na)、甜菊苷用量,并对最优处方所制制剂进行验证。结果:最优处方组成为(片质量60 mg):硫酸吗啡16.67%、SMCC 35.77%、CCMC-Na 8.94%、甜菊苷2.85%、硬脂酸镁1%、甘露醇34.77%。所制口腔崩解片硬度为3 kg,能在12 s内完全崩解,且味微甜、口感良好。结论:该制剂制备方法简便、可行。     

Evaluation of Disintegrating Time of Rapidly Disintegrating Tablets by a Paddle Method

A paddle method for measurement of the disintegrating time of orally disintegrating tablets with rizatriptan benzoate as a model drug was evaluated. The paddle method employed a dissolution test assembly with tablets immersed in disintegrating medium through a fastened sinker. Paddle stirring rate, opening of the sinker sieve, and tablet crushing strength influenced disintegrating time greatly. A logarithmic relationship was observed between disintegrating time and paddle revolution speed, while disintegrating time values and tablet crushing strength were fitted to a linear equation. The paddle method values with limited deviation were in good correlation with in vivo results. The paddle method was employed to optimize the disintegrating time of rizatriptan benzoate orally disintegrating tablets using a factorial design. The best-fit quadratic equation with a regression coefficient of 0.996 was highly predictive, which was indicative that the paddle method was precise and applicable in formulation optimization.     

Evaluation of disintegrating time of rapidly disintegrating tablets by a paddle method

A paddle method for measurement of the disintegrating time of orally disintegrating tablets with rizatriptan benzoate as a model drug was evaluated. The paddle method employed a dissolution test assembly with tablets immersed in disintegrating medium through a fastened sinker. Paddle stirring rate, opening of the sinker sieve, and tablet crushing strength influenced disintegrating time greatly. A logarithmic relationship was observed between disintegrating time and paddle revolution speed, while disintegrating time values and tablet crushing strength were fitted to a linear equation. The paddle method values with limited deviation were in good correlation with in vivo results. The paddle method was employed to optimize the disintegrating time of rizatriptan benzoate orally disintegrating tablets using a factorial design. The best-fit quadratic equation with a regression coefficient of 0.996 was highly predictive, which was indicative that the paddle method was precise and applicable in formulation optimization.     

单硝酸异山梨酯口崩片的制备及质量评价

目的制备单硝酸异山梨酯口崩片并评价其质量。方法直接粉末压片法制备口腔崩解片。以片剂崩解时限、口感为指标,采用正交试验设计优化处方,并与普通片进行了体外溶出度的比较。结果 采用优选方法制备的单硝酸异山梨酯口崩片崩解时间在30 s内,5 min释药85%以上。结论单硝酸异山梨酯口崩片处方设计合理,制备工艺可行,质量可控。     

兰索拉唑微丸口崩片的制备及崩解时间测定方法考察

目的：制备兰索拉唑微丸口崩片，考察崩解时间的测定方法。方法：采用粉末直接压片法制备口崩片，并以填充剂、崩解剂及润滑剂的种类和用量作为考察因素，通过单因素试验和正交试验结果确定最优处方。崩解时间的测定方法分别为药典法Ⅰ、药典法Ⅱ和改良法，将3种方法的结果进行比较，选择合适的测定方法用于处方筛选。结果：用改良法测定崩解时间可以较好区分不同处方间的差别。口崩片的优化处方为30%兰索拉唑微丸，59%微晶纤维素102，5%交联羧甲基纤维素钠，5.5%甘露醇，0.5%硬脂富马酸钠。结论：改良法适用于处方筛选时对崩解时间的测定，优化处方制备的口崩片崩解迅速。     

Disintegrating force as a new formulation parameter

Some coated aspirin tablet formulations were evaluated by relating their properties to disintegrating force development patterns. The treatment of disintegrating force-time curves was effected using the Weibull distribution as proposed for dissolution. Such parameters as the maximum disintegrating force developed, the time needed to reach 63.2% maximum disintegrating force (tau d) the shape parameter, the lag time, and the input value were used for evaluating the formulas examined. It was concluded that the input values, the integrating force development rate at tau d, can be employed as a new formulation parameter since, when correlated with the crushing strength, it allows an overall evaluation of the formula examined.